With Inotuzumab the situation is clear - monocloal antiodies as targeted treatment is not efficient, but failure of Arbaclofen placarbil is not very ... classical. The concept of prodrug design sometimes looks too mechanistic but always rational. But to be "rational" is not enough in order to be "efficient"...
No comments:
Post a Comment